Want to meet with representatives from Sprint Bioscience to hear what we have in our pipeline and how we look upon the field?

Meet us at AACR in Washington April 6-10 or at BIO 2013 in Chicago April 21-25 .

The editorial board of SYNFACTS, a journal that summarise the current most significant results from the primary literature within synthetic organic chemistry, has selected our chemistry team member Johan Lindström’s latest publication, One-Pot Synthesis of 5-Acyl-2-amino-1,3,4-thiadiazoles, Lindström and Hallberg, Synthesis 2012, 44, for its important insights.

The motivation for the selection by SYNFACTS states; “This new synthesis of 2-amino-1,3,4-thiadiazoles should prove useful due to its experimental simplicity, reasonable substrate scope and its use of easily accessible or commercially available reagents.”

The SYNFACTS article is available online (to subscribers only) via http://www.thieme-connect.com/ejournals/toc/synfacts.

New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain
http://pubs.acs.org/doi/abs/10.1021/jm300991n

Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides
http://pubs.acs.org/doi/abs/10.1021/jm3009025

30 October 2012: TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.

Under the terms of the agreement TPP and Sprint Bioscience will work together to further the development of small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer. Tom Brown, TPP’s CEO commented, “We are delighted to have entered into this agreement to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development. Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio.”
For more information please visit www.tppgd.com

Notes to Editors:

TPP Global Development
TPP is a UK-based, biotechnology company focused on developing preclinical drug development programmes around three main therapeutic areas: oncology, neuro-degeneration, immunology/inflammation. By combining proven drug development expertise with a sharp commercial focus, TPP is progressing a portfolio of novel chemical assets within the disease areas listed above. Globally, TPP has established an extensive network of collaborations with leading life science research institutes and other industry participants allowing it access to the most exciting, emerging therapeutic targets and pathways.

Sprint Biosciences AB
Sprint Bioscience is a Swedish company developing oncology therapeutics targeting cancer metabolism, founded by experienced drug developers with an ambition to improve the drug discovery process. The company has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time.

Contacts:

TPP Global Development
Peter Trill, Co-founder & CFO
Ph: +44 (0)131 523 1428
Email: peter.trill@tppgd.com

or

Sprint Bioscience AB
Anne-Marie Wenthzel
Director of Business Development
Ph: +46 (0) 8-411 44 55
Email: amw@sprintbioscience.com

View or download press release

SPRINT BIOSCIENCE STRENGTHENS ITS CANCER METABOLISM PORTFOLIO

Sprint Bioscience, a Swedish company developing oncology therapeutics targeting cancer metabolism, announced today that it has raised money to strengthen its drug discovery portfolio.

The investment by Första Entreprenörsfonden and Almi Invest will enable the company to continue to build a pipeline of drug discovery projects within cancer metabolism.

“We are investing in Sprint Bioscience because we consider their entrepreneurial drive and their particular skills in drug development to be key success factors for the changing environment of the future pharmaceutical industry. Sprint Bioscience’s business strategy involves out-licensing or collaborating at an early stage of drug discovery to ensure that projects are developed with a focus on current and relevant market needs,” says Rune Nordlander, partner at Första Entreprenörsfonden.

Sprint Bioscience is a company founded by experienced drug hunters with an ambition to improve the drug discovery process. “We believe in small organisations with effective working procedures and collaborations throughout the sector,” says the company’s CEO and co-founder, Dr. Anders Åberg.

“Sprint Bioscience has developed an efficient, fragment-based drug discovery (FBDD) platform that can take parallel projects from initial idea to active molecules tested in cell-based systems in a very short time” Anders Åberg continues. Our goal is to align the early phase in the laboratory with pharmaceutical companies’ needs.

Targeting the metabolism in tumours provides exciting opportunities to develop drug therapies with novel mechanisms of action. This could be used to overcome the resistance that many cancer cells develop to current treatments.

###

For further information, please contact:

Anne-Marie Wenthzel, Director Business Development, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-739 399 330
E-mail: amw@sprintbioscience.com

Anders Åberg, CEO and co-founder, Sprint Bioscience AB
Tel: +46-8-411 44 55
Cell Phone: +46-762 738 777
E-mail: anders.aberg@sprintbioscience.com

sprintbioscience.com

Chemical Synthesis, Chemical Design, Computational Chemistry, Drug Discovery and Development, Project Management, IP Strategies, Cell Biology, Cell-Based Assays, Molecular Biology, Protein Purification, Assays, Screening, Biophysics, Structural Biology, Protein Crystallography

We are happy to welcome our new colleagues to our team!

The Team at Sprint Bioscience. Three members missing in the picture